A new clinical study has been released this year that is demonstrating promising treatment options for pancreatic cancer. Background: Available 2L therapies offer limited clinical benefit in mPDAC with reported mPFS of 3–4 mo and mOS of 6–7 mo. Aberrant RAS pathway activation is the key driver of PDAC, with oncogenic RAS mutations (mut) identified …
Continue reading “Major Cancer Breakthrough in Pancreatic Cancer Treatment”